Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
about
Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression.Exploiting Epigenetic Alterations in Prostate Cancer.Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer.Therapeutic management of bone metastasis in prostate cancer: an update.Androgen Signaling in Prostate Cancer.
P2860
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase I and II therapies targe ...... ion resistant prostate cancer.
@en
type
label
Phase I and II therapies targe ...... ion resistant prostate cancer.
@en
prefLabel
Phase I and II therapies targe ...... ion resistant prostate cancer.
@en
P2860
P1476
Phase I and II therapies targe ...... ion resistant prostate cancer.
@en
P2093
Athanasios Dellis
Athanasios G Papatsoris
P2860
P304
P356
10.1517/13543784.2016.1162784
P407
P577
2016-03-08T00:00:00Z